论文部分内容阅读
随着强烈化疗和骨髓移植的进展 ,中青年急性髓细胞白血病 (AML)的完全缓解率和长期无病生存率不断提高[1] ,而老年人AML的疗效比儿童和成人的疗效差得多[2 ] 。因此 ,老年人AML的治疗已成为一个令人关注的问题。我们对我院 3 0例老年AML患者使用不同剂量HA(VP16)、DA(VP16)方案
With intensive chemotherapy and bone marrow transplantation, the complete remission rate and long-term disease-free survival rate of acute myeloid leukemia (AML) in middle-aged and young adults are continuously increasing [1], while the efficacy of AML in the elderly is much worse than that in children and adults [2 ] . Therefore, the treatment of elderly AML has become a cause for concern. We used 30 doses of HA (VP16) and DA (VP16) to treat 30 elderly AML patients in our hospital